Flavio Solca

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

Systems Biology, Medicine, Bronchial Neoplasm +8

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, G. Dahl, Andreas Zoephel et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 848 citations

Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells.

Walter Siegrist, Flavio Solca, Sibylla Stutz et al. · PubMed · 1989 · 222 citations

Immunology, Tumor Biology, Photoaffinity Cross-linking +18

Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation

Sun Mi Kim, Oh-Joon Kwon, Yun Hong et al. · Molecular Cancer Therapeutics · 2012 · 194 citations · Full text

Irreversible Egfr Inhibitors, Cell Signaling, T790m Resistance Mutation +13

HER2 ^YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

Samanthi A. Perera, Danan Li, Takeshi Shimamura et al. · Proceedings of the National Academy of Sciences · 2009 · 178 citations · Full text

Immunology, Pathology, Cancer Biology +17